These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 28082437

  • 1. Whole-Body 18F-FDG PET/CT Is Superior to CT as First-Line Diagnostic Imaging in Patients Referred with Serious Nonspecific Symptoms or Signs of Cancer: A Randomized Prospective Study of 200 Patients.
    Lebech AM, Gaardsting A, Loft A, Graff J, Markova E, Bertelsen AK, Madsen JL, Andersen KF, Benzon EV, Helms M, Mathiesen LR, David KP, Kronborg G, Kjaer A.
    J Nucl Med; 2017 Jul; 58(7):1058-1064. PubMed ID: 28082437
    [Abstract] [Full Text] [Related]

  • 2. Whole-Body 18F-FDG PET and 18F-FDG PET/CT in Patients with Suspected Paraneoplastic Syndrome: A Systematic Review and Meta-Analysis of Diagnostic Accuracy.
    Sheikhbahaei S, Marcus CV, Fragomeni RS, Rowe SP, Javadi MS, Solnes LB.
    J Nucl Med; 2017 Jul; 58(7):1031-1036. PubMed ID: 27980049
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic performance of 18F-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma.
    Ishiguchi H, Ito S, Kato K, Sakurai Y, Kawai H, Fujita N, Abe S, Narita A, Nishio N, Muramatsu H, Takahashi Y, Naganawa S.
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [Abstract] [Full Text] [Related]

  • 4. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
    Robin P, Le Roux PY, Planquette B, Accassat S, Roy PM, Couturaud F, Ghazzar N, Prevot-Bitot N, Couturier O, Delluc A, Sanchez O, Tardy B, Le Gal G, Salaun PY, MVTEP study group.
    Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A.
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [Abstract] [Full Text] [Related]

  • 7. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Diagnostic Accuracy of 18F-FDG PET/CT in Infective Endocarditis and Implantable Cardiac Electronic Device Infection: A Cross-Sectional Study.
    Granados U, Fuster D, Pericas JM, Llopis JL, Ninot S, Quintana E, Almela M, Paré C, Tolosana JM, Falces C, Moreno A, Pons F, Lomeña F, Miro JM, Hospital Clinic Endocarditis Study Group.
    J Nucl Med; 2016 Nov; 57(11):1726-1732. PubMed ID: 27261514
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 17. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS, Shahin MA.
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [Abstract] [Full Text] [Related]

  • 18. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary.
    Wang G, Wu Y, Zhang W, Li J, Wu P, Xie C.
    J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia.
    Zhou WL, Wu HB, Wang LJ, Tian Y, Dong Y, Wang QS.
    Eur J Radiol; 2016 Jan; 85(1):205-210. PubMed ID: 26724667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.